Emergent BioSolutions Inc. EBS 深 滬
已收盤 08-07 16:00:00 美东时间
4.84
-0.470
-8.85%
華盛通- 最 高5.55
- 今 開5.40
- 成交量 314.07万股
- 最 低 4.81
- 昨 收 5.31
- 總市值 2.50亿
- 52周最高 14.06
- 市盈率 靜 5.22
- 換手率 6.09%
- 52周最低 4.81
- 委 比 30.64%
- 總股本 5159.63万
- 歷史最高 137.61
- 量 比 2.45
- 振 幅 13.94%
- 歷史最低 1.42
- 每 手 1
- 風險率 1.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Emergent BioSolutions shares are trading lower after the company lowered its FY2026 sales guidance.
Emergent BioSolutions shares are trading lower after the company lowered its FY2026 sales guidance.
08-06 04:58
Emergent BioSolutions Sees Q3 Sales $110.000M-$130.000M vs $209.000M Est
Emergent BioSolutions (NYSE:EBS) sees Q3 sales of $110.000 million-$130.000 million vs $209.000 million analyst estimate.
08-06 04:51
Emergent BioSolutions 2026年第二季度财报：MCM放量推升营收，全年指引下调
Emergent BioSolutions第二季度营收2.343亿美元，同比增长66%，稀释每股亏损3.49美元，调整后EBITDA为9,650万美元；MCM交付增长，但NARCAN减值及全年指引下调构成主要压力。
08-05 21:05
Emergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026
Emergent BioSolutions will host a conference call on August 5, 2026, at 5:00 p.m. ET to discuss Q2 2026 financial results. Participants can join via webcast, the Investors page, or telephone by registering in advance. A replay will be available on the Investors page. The company focuses on developing life-saving solutions for health threats. For more information, contact Investor Relations at lindahlr@ebsi.com or Media Relations at mediarelations...
07-22 20:01
Emergent BioSolutions 获得新ACAM2000生物防御合同
Emergent BioSolutions（股票代码EBS）披露最新业务及资本市场相关动态。 2026年6月26日，公司收到美国卫生与公众服务部ASPR授予的价...
06-30 10:34
Emergent BioSolutions获5270万美元天花疫苗合同
Emergent BioSolutions获得美国卫生与公众服务部价值5270万美元的合同修订订单，供应ACAM2000天花疫苗、配套耗材及替代批次稀释剂，预计...
06-29 21:25
Emergent BioSolutions Secures $52.7M U.S. Government Contract Modification For ACAM2000 Smallpox And Mpox Vaccine Supply
Emergent BioSolutions (NYSE:EBS) today announced it has been awarded a contract modification valued at $52.7 million from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services to supply ACAM2000® (Smallpox and Mpox (Vaccinia) V...
06-29 21:13
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
Emergent BioSolutions has been awarded a $52.7 million contract modification by the U.S. Department of Health and Human Services to supply ACAM2000® vaccine for smallpox and mpox preparedness. The company emphasizes its role in biodefense and highlights recent approvals in Saudi Arabia and Singapore for expanded use of the vaccine. ACAM2000® is indicated for high-risk individuals and carries important safety warnings, including potential serious ...
06-29 13:13
Emergent BioSolutions Wins $64.5M U.S. HHS Contract Modification To Supply Botulism Antitoxin BAT Under Existing 10-Year Agreement
Emergent BioSolutions Inc. (NYSE:EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response (ASPR), a division
05-29 04:22
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
Emergent BioSolutions Inc. has been awarded a $64.5 million contract modification from the U.S. Department of Health and Human Services to supply BAT®, an antitoxin for treating botulism, under a 10-year agreement. The company highlights its commitment to U.S. biodefense and preparedness, leveraging its North American supply chain to deliver critical medical countermeasures. BAT® is indicated for treating symptomatic botulism in adults and pediat...
05-28 20:01
